白云山/华润医药/药明生物逆升约2% 惟石四药(02005.HK)失牛熊线
港股扭两连升今天显着回吐，恒指受汇控(00005.HK)去年业绩逊预期拖累午後曾失守10天线(27,542)，低见27,496，守稳20天线(27,468)，现造27,583，回吐376点或1.3%；国指回吐1.2%报10,828。
不过，部分获里昂看好药股逆市造好，获里昂升目标价36%至139.69元及给予「买入」评级的药明生物(02269.HK)继昨天升至121.3元屡创纪录高遇压轻微倒跌後，今天反覆(早段曾低见114.2元)回升，午後股价高见120.2元，现造119.4元，回升2.3%，报成交281万股。
同获里昂给予「买入」看14.21元的华润医药(03320.HK)旗下药品NIP292获得美国食品药品监督管理局(FDA)授予治疗特发性肺纤维化(IPF)孤儿药资格。该股高见7.59元，现造7.55元，续升1.9%。此外，子公司将恢复复磷酸氯(口奎)片生产的白云山(00874.HK)曾一举重越10天及20天线(26.04元及26.4元)，最高见27.2元，现造26.15元，续升1.8%。
不过，蓝筹中生制药(01177.HK)及石药(01093.HK)低见11.36元及18.92元，现造11.54元及19.02元，续吐1.9%及1.8%，後者股价失守10天线(19.13元)。此外，石四药(02005.HK)六连跌，今天股价失守牛熊线(6.75元)，现造6.7元即市低位，续跌2.5%。
四环医药(00460.HK)续吐2.9%报1元，略失10天线(1.01元)；三生制药(01530.HK)跌1.5%报10.78元，略失10天线(10.8元)。
里昂昨天表示，内地推出辅助药物名单、新版国家药品报销清单，以及全国第一批集中采购扩大和第二批集中采购启动等政策，相信旨在优化公共医疗保健预算，削减昂贵/临床不必要药物的公共资源，同时鼓励创新。基於「4+7」政策中药品及实施地区数量有限，预计药品制造公司将保持增长势头，且预料分销商在第四季表现将保持首三季势头。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
